GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Minerva Surgical Inc (OTCPK:UTRS) » Definitions » Cash Flow from Financing

Minerva Surgical (Minerva Surgical) Cash Flow from Financing : $26.86 Mil (TTM As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Minerva Surgical Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Sep. 2023, Minerva Surgical paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Minerva Surgical spent $0.00 Mil on financial activities for the three months ended in Sep. 2023.


Minerva Surgical Cash Flow from Financing Historical Data

The historical data trend for Minerva Surgical's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minerva Surgical Cash Flow from Financing Chart

Minerva Surgical Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Cash Flow from Financing
43.16 18.08 46.21 -4.96

Minerva Surgical Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - 26.77 0.08 -

Minerva Surgical Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Minerva Surgical's Cash from Financing for the fiscal year that ended in Dec. 2022 is calculated as:

Minerva Surgical's Cash from Financing for the quarter that ended in Sep. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $26.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Minerva Surgical  (OTCPK:UTRS) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Minerva Surgical's issuance of stock for the three months ended in Sep. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Minerva Surgical's repurchase of stock for the three months ended in Sep. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Minerva Surgical's net issuance of debt for the three months ended in Sep. 2023 was $0.00 Mil. Minerva Surgical received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Minerva Surgical's net issuance of preferred for the three months ended in Sep. 2023 was $0.00 Mil. Minerva Surgical paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Minerva Surgical's cash flow for dividends for the three months ended in Sep. 2023 was $0.00 Mil. Minerva Surgical received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Minerva Surgical's other financing for the three months ended in Sep. 2023 was $0.00 Mil. Minerva Surgical received $0.00 Mil on other financial activities.


Minerva Surgical Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Minerva Surgical's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Minerva Surgical (Minerva Surgical) Business Description

Traded in Other Exchanges
N/A
Address
4255 Burton Drive, Santa Clara, CA, USA, 95054
Minerva Surgical Inc is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company operates and manages its business as one reportable and operating segment, which is the business of research, development, and sale of therapeutic devices for abnormal uterine bleeding treatment.
Executives
Daniel Cohen director C/O ACCELMED, 848 BRICKELL AVE, #901, MIAMI FL 33131
Accelmed Partners Ii L.p. 10 percent owner 2875 NE 191ST, SUITE 500, AVENTURA FL 33180
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Uri Geiger director, 10 percent owner 221 LATHROP WAY, SUITE I, SACRAMENTO CA 95815
Todd Usen director, officer: Chief Executive Officer C/O MINERVA SURGICAL, INC., 4255 BURTON DRIVE, SANTA CLARA CA 95054
Derrick Sung director C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103
David M Clapper director, officer: President and CEO 3003 TASMAN DRIVE, SANTA CLARA CA 95054
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Jaffe Ross A Md director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Evgueni V. Skalnyi officer: VP Medical Affairs C/O MINERVA SURGICAL, INC., 4225 BURTON DRIVE, SANTA CLARA CA 95054
Dominique J. Filloux officer: COO C/O MINERVA SURGICAL, INC., 4225 BURTON DRIVE, SANTA CLARA CA 95054
Joel R Jung officer: CFO 1401 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Niquette L. Hunt director SOLITON, INC., 5304 ASHBROOK DRIVE, HOUSTON TX 77081
Jill Anderson director 1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095
Nea Partners 13, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202

Minerva Surgical (Minerva Surgical) Headlines